DK0661973T3 - Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade - Google Patents

Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade

Info

Publication number
DK0661973T3
DK0661973T3 DK93923724T DK93923724T DK0661973T3 DK 0661973 T3 DK0661973 T3 DK 0661973T3 DK 93923724 T DK93923724 T DK 93923724T DK 93923724 T DK93923724 T DK 93923724T DK 0661973 T3 DK0661973 T3 DK 0661973T3
Authority
DK
Denmark
Prior art keywords
nmda receptor
mediated neuronal
procedure
receptor complex
mammal
Prior art date
Application number
DK93923724T
Other languages
English (en)
Inventor
Stuart A Lipton
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/949,342 external-priority patent/US5234956A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of DK0661973T3 publication Critical patent/DK0661973T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK93923724T 1992-09-22 1993-09-22 Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade DK0661973T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/949,342 US5234956A (en) 1991-04-19 1992-09-22 Method of preventing NMDA receptor complex-mediated neuronal damage
US08/025,028 US5455279A (en) 1991-04-19 1993-03-02 Regimen method of mediating neuronal damage using nitroglycerine

Publications (1)

Publication Number Publication Date
DK0661973T3 true DK0661973T3 (da) 2006-10-30

Family

ID=26699179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93923724T DK0661973T3 (da) 1992-09-22 1993-09-22 Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade

Country Status (8)

Country Link
US (3) US5455279A (da)
EP (1) EP0661973B1 (da)
AT (1) ATE330606T1 (da)
AU (1) AU5348194A (da)
DE (1) DE69334035T2 (da)
DK (1) DK0661973T3 (da)
ES (1) ES2264122T3 (da)
WO (1) WO1994006428A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
CA2159106C (en) * 1993-04-20 2009-10-06 Lorrie P. Daggett Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US5807847A (en) * 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
CA2264959A1 (en) * 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Central nervous system-derived immune privilege factor and uses thereof
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
HUP0002859A2 (hu) * 1997-07-11 2001-01-29 The Johns Hopkins University School Of Medicine A nitrogén-monoxidot kibocsátó vegyületek alkalmazása rinovírus-fertőzés által előidézett kórtünetek enyhítésére
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
JPH11217330A (ja) * 1998-01-30 1999-08-10 Sumitomo Pharmaceut Co Ltd 神経栄養因子分泌促進剤
EP1013272A1 (en) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation of the activity of a nitric oxide radical production pathway for the treatment of diseases associated with the presence of oxygen free radicals
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US6255280B1 (en) 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
GB9908175D0 (en) * 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6432434B1 (en) * 1999-04-22 2002-08-13 The United States Of America As Represented By The Secretary Of The Army Treatment of and/or prophylaxis against brain and spinal cord injury
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
AU5601300A (en) * 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US7820420B2 (en) * 2000-08-11 2010-10-26 Whitlock David R Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
EP1852113A3 (en) * 2000-12-07 2008-03-12 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with NMDA receptors antagonists
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
EP1472021A4 (en) * 2002-01-11 2008-04-16 David R Whitlock AMMONIA OXIDIZING BACTERIUM COMPOSITIONS AND METHODS OF USE
US20030229114A1 (en) * 2002-04-04 2003-12-11 Rosenberg Paul A. Pyrroloquinoline quinone drugs as a neuroprotectant and methods of use thereof
US20050148673A1 (en) * 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US20070148136A1 (en) * 2003-09-26 2007-06-28 Whitlock David R Methods of using ammonia oxidizing bacteria
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
ES2483126T3 (es) 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
WO2007116458A1 (ja) * 2006-03-30 2007-10-18 Tohru Hasegawa 神経変性疾患治療薬
JP5228912B2 (ja) * 2006-09-08 2013-07-03 三菱瓦斯化学株式会社 高血圧改善剤
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
IT1398507B1 (it) * 2009-01-13 2013-03-01 Giellepi Chemicals S P A Composizione per il trattamento di neuropatie
US9023890B2 (en) * 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
NZ601635A (en) 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
US9452117B2 (en) 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
EP2948135B1 (en) 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
JP2017519486A (ja) 2014-04-15 2017-07-20 エーオーバイオーム， エルエルシー．ＡＯＢｉｏｍｅ， ＬＬＣ． アンモニア酸化Ｎｉｔｒｏｓｏｍｏｎａｓ ｅｕｔｒｏｐｈａ株Ｄ２３
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
CH603545A5 (da) * 1972-04-20 1978-08-31 Merz & Co
US4064139A (en) * 1975-04-07 1977-12-20 Merck & Co., Inc. Substituted 9,10-dihydroanthracen-9,10-imines
US4399141A (en) * 1977-09-19 1983-08-16 Merck & Co., Inc. 5-Alkyl or hydroxyalkyl substituted-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines and anticonvulsant use thereof
US4374838A (en) * 1977-09-19 1983-02-22 Merck & Co., Inc. Dibenzo[a,d]cycloocten-5,12-(and 6,12)-imines
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4513137A (en) * 1981-04-09 1985-04-23 The University Of Akron Iodonium salts
US4351847A (en) * 1981-06-26 1982-09-28 Pennwalt Corporation Antiviral alpha, alpha-dialkyl adamantylethylamines
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists
US4736048A (en) * 1986-06-04 1988-04-05 Dow Corning Corporation Pressure sensitive adhesive release liner and fluorosilicone compounds, compositions and method therefor
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
DE3856401D1 (de) * 1987-01-23 2000-05-04 Gen Hospital Corp Hydralazin zur topischen Behandlung von Glaukom
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
ES2059602T3 (es) * 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5264371A (en) * 1989-11-22 1993-11-23 Neurex Corporation Screening method for neuroprotective compounds
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5091391A (en) * 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
WO1992018112A1 (en) * 1991-04-19 1992-10-29 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage

Also Published As

Publication number Publication date
ES2264122T3 (es) 2006-12-16
DE69334035D1 (de) 2006-08-03
EP0661973B1 (en) 2006-06-21
AU5348194A (en) 1994-04-12
EP0661973A1 (en) 1995-07-12
US5747545A (en) 1998-05-05
ATE330606T1 (de) 2006-07-15
DE69334035T2 (de) 2006-12-28
US5801203A (en) 1998-09-01
US5455279A (en) 1995-10-03
EP0661973A4 (en) 1999-12-22
WO1994006428A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
DE69334035D1 (de) Verfahren zur vorbeugung von nmda-rezeptor vermittelten neuronalen schäden
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
DK0557385T3 (da) Topiske sammensætninger til transdermal afgivelse af prodrug-derivater af morfin
ES2134804T3 (es) Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
BG40955A3 (en) Acaricide means and method for protection from acars
FI932254A7 (fi) Menetelmä dipalmitoyylifosfaridyylikoliinidispersioiden antamiseksi
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
ATE121086T1 (de) Sulfonylbenzyl-substituierte benzo- und pyridopyridone.
ATE164159T1 (de) Substituierte triole
ATE348812T1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
FI920508L (fi) Saett vid tandbehandling.
DE59200469D1 (de) Verfahren zum mehrstufigen bearbeiten von zähnen an sägeblättern sowie sägenbearbeitungsmaschine zum durchführen des verfahrens.
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
NO890046D0 (no) Disubstituerte pyridiner.
DE69217003D1 (de) N-phenyl-benzamide zum schutz vor den schädlichen wirkungen von ultraviolettlicht
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
DK16389D0 (da) Anvendelse af en blanding til behandling af alopecia
FI891473A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
DK0802796T3 (da) Kyllingeanæmimiddel-slagtekyllingevaccine
SE9904289D0 (sv) Method and camposition for the treatment of adenovairal ocular infections
DK211189A (da) Fremgangsmaade til fremstilling af 5-chlor-3-chlorsulfonyl-2-thiophencarboxylsyreestere
AU2550092A (en) A device for securing two or more seismic energy sources at fixed relative positions